市場調查報告書

先進癌症性疼痛管理 - 市場考察,流行病學,市場預測:2028年

Advanced Cancer Pain Management (ACPM) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 923097
出版日期 內容資訊 英文 142 Pages
商品交期: 最快1-2個工作天內
價格
先進癌症性疼痛管理 - 市場考察,流行病學,市場預測:2028年 Advanced Cancer Pain Management (ACPM) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 142 Pages
簡介

本報告提供全球先進癌症性疼痛管理市場相關調查分析,提供疾病的背景,流行病學,主要7個國家 (美國,德國,西班牙,義大利,法國,英國,日本)的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 先進癌症性疼痛管理市場概要

  • 先進癌症性疼痛管理的市場佔有率:2017年
  • 先進癌症性疼痛管理的市場佔有率:2018年

第3章 疾病的背景和概要

  • 簡介
  • 病因和種類
  • 癌症性疼痛的分類系統
  • 癌症性疼痛的病理生理學
  • 癌症性疼痛症候群
  • 疼痛臨床症狀與評估

第4章 流行病學和患者族群

  • 主要調查結果
  • 主要7個國家的癌症性疼痛的發生率
  • 前提條件與根據:主要7個國家
  • 預測的參數

第5章 各國流行病學

  • 美國
  • EU5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 治療和管理

  • NCCN指南
  • ESMO臨床診療指南
  • 西班牙的指南
  • 癌症性疼痛的五花八門個體化管理
  • 患者的旅行
  • 癌症性疼痛管理上大麻素所扮演的角色

第7章 未滿足需求

第8章 案例研究

  • 疼痛管理的案例研究:癌症性疼痛
  • 癌症相關的內臟痛
  • 複雜的疼痛管理:案例研究

第9章 新興藥

  • PPP011:Tetra Bio-Pharma Inc.
  • Halneuron:Wex Pharma
  • Tanezumab:Pfizer

第10章 其他目標產品

  • Tetrodotoxin:Wex Pharma
  • Sativex:GW Pharmaceuticals
  • NPC-06:Nobelpharma

第11章 先進癌症性疼痛管理:主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的先進癌症性疼痛管理的市場規模
  • 市場預測:主要7個國家
  • 預測參數
  • 美國的市場規模

第12章 EU5個國家:市場規模

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本:市場規模

  • 日本的市場規模
    • 先進癌症性疼痛管理的整體市場規模
    • 市場規模:各療法

第14章 推動市場要素

第15章 市場障礙

第16章 附錄

第17章 DelveInsight的功能

第18章 免責事項

第19章 關於DelveInsight

目錄
Product Code: DIMI0831

DelveInsight's 'Advanced Cancer Pain Management(ACPM) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ACPMs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Advanced Cancer Pain Management (ACPM) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Advanced Cancer Pain Management (ACPM) - Disease Understanding and Treatment Algorithm

Pain is the commonest symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients' life quality and caregiver distress. This includes different types of pain such as neuropathic, incident or breakthrough, and bone pain associated with poor pain control and with a negative impact on physical, cognitive, and social functioning and mood.

The DelveInsight Advanced Cancer Pain Management (ACPM) market report gives the thorough understanding of the Advanced Cancer Pain Management by including details such as disease definition, classification, symptoms, etiology, pathophysiology and clinical assessment. It also provides treatment algorithms and treatment guidelines for Advanced Cancer Pain Management in the US and Europe.

Advanced Cancer Pain Management Epidemiology

The Advanced Cancer Pain Management (ACPM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Advanced Stage Cancers, Incidence of Cancer Pain based on Etiologies, Incidence of Chemotherapy Induced Peripheral Neuropathy, Severity Based Incidence of Cancer Pain, Total Incidence of Cancer Pain based on Pathophysiology, Incidence of Cancer Pain based on Temporal Variations, Incidence of Breakthrough Pain, Incidence of Cancer Pain based on duration) scenario of Advanced Cancer Pain Management (ACPM) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Advanced Cancer Pain Management (ACPM) in 7 MM was found to be 1,537,681, in the year 2017.

Advanced Cancer Pain Management Drug Chapters

This segment of the Advanced Cancer Pain Management report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Opioid based treatments are the mainstay of moderate-to-severe cancer-related pain. The goal of long-term opioid treatment is to provide sustained, clinically meaningful relief of pain with side effects that are tolerable and an overall benefit to quality of life.

Advanced Cancer Pain Management Market Outlook

The Advanced Cancer Pain Management market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Advanced Cancer Pain Management in 7MM was found to be USD 871.50 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Acute Bacterial Prostatitis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Advanced Cancer Pain Management Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Advanced Cancer Pain Management Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key strengths

  • 9 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Key assessments

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Advanced Cancer Pain Management market
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Cancer Pain Management market
  • To understand the future market competition in the Advanced Cancer Pain Management market.

Table of Contents

1. Key Insights

2. Advanced Cancer Pain Management Market Overview at a Glance

  • 2.1. Market Share (%) of Advanced Cancer Pain Management in 2017 - 7MM
  • 2.2. Market Share (%) of Advanced Cancer Pain Management in 2028 - 7MM

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Etiology and types
  • 3.3. Cancer Pain Classification Systems
    • 3.3.1. International Association for the Study of Pain (IASP) Taxonomy
    • 3.3.2. ICD-11
    • 3.3.3. Edmonton Classification System for Cancer Pain (ECS-CP)
  • 3.4. Cancer Pain Pathophysiology
  • 3.5. Cancer Pain Syndromes
  • 3.6. Clinical Presentation and Assessment of Pain

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Incidence of Cancer Pain based on Etiologies in 7MM
  • 4.3. Assumptions and Rationale: 7MM
  • 4.4. Forecast Parameters

5. Country Wise-Epidemiology

  • 5.1. The United States
    • 5.1.1. Total Incident Cases of Advanced Stage Cancers in the United States
    • 5.1.2. Incidence of Cancer Pain based on Etiologies in the United States
    • 5.1.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the United States
    • 5.1.4. Severity Based Incidence of Cancer Pain on in the United States
    • 5.1.5. Total Incidence of Cancer Pain based on Pathophysiology in the United States
    • 5.1.6. Incidence of Cancer Pain based on Temporal Variations in the United States
    • 5.1.7. Incidence of Breakthrough Pain in the United States
    • 5.1.8. Incidence of Cancer Pain based on duration in the United States
  • 5.2. EU-5
  • 5.3. Germany
    • 5.3.1. Total Incident Cases of Advanced Stage Cancers in Germany
    • 5.3.2. Incidence of Cancer Pain based on Etiologies in Germany
    • 5.3.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany
    • 5.3.4. Severity Based Incidence of Cancer Pain on in Germany
    • 5.3.5. Total Incidence of Cancer Pain based on Pathophysiology in Germany
    • 5.3.6. Incidence of Cancer Pain based on Temporal Variations in Germany
    • 5.3.7. Incidence of Breakthrough Pain in Germany
    • 5.3.8. Incidence of Cancer Pain based on duration in Germany
  • 5.4. France
    • 5.4.1. Total Incident Cases of Advanced Stage Cancers in France
    • 5.4.2. Incidence of Cancer Pain based on Etiologies in France
    • 5.4.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in France
    • 5.4.4. Severity Based Incidence of Cancer Pain on in France
    • 5.4.5. Total Incidence of Cancer Pain based on Pathophysiology in France
    • 5.4.6. Incidence of Cancer Pain based on Temporal Variations in France
    • 5.4.7. Incidence of Breakthrough Pain in France
    • 5.4.8. Incidence of Cancer Pain based on duration in France
  • 5.5. Italy
    • 5.5.1. Total Incident Cases of Advanced Stage Cancers in Italy
    • 5.5.2. Incidence of Cancer Pain based on Etiologies in Italy
    • 5.5.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy
    • 5.5.4. Severity Based Incidence of Cancer Pain on in Italy
    • 5.5.5. Total Incidence of Cancer Pain based on Pathophysiology in Italy
    • 5.5.6. Incidence of Cancer Pain based on Temporal Variations in Italy
    • 5.5.7. Incidence of Breakthrough Pain in Italy
    • 5.5.8. Incidence of Cancer Pain based on duration in Italy
  • 5.6. Spain
    • 5.6.1. Total Incident Cases of Advanced Stage Cancers in Spain
    • 5.6.2. Incidence of Cancer Pain based on Etiologies in Spain
    • 5.6.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain
    • 5.6.4. Severity Based Incidence of Cancer Pain on in Spain
    • 5.6.5. Total Incidence of Cancer Pain based on Pathophysiology in Spain
    • 5.6.6. Incidence of Cancer Pain based on Temporal Variations in Spain
    • 5.6.7. Incidence of Breakthrough Pain in Spain
    • 5.6.8. Incidence of Cancer Pain based on duration in Spain
  • 5.7. United Kingdom
    • 5.7.1. Total Incident Cases of Advanced Stage Cancers in United Kingdom
    • 5.7.2. Incidence of Cancer Pain based on Etiologies in United Kingdom
    • 5.7.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in United Kingdom
    • 5.7.4. Severity Based Incidence of Cancer Pain on in United Kingdom
    • 5.7.5. Total Incidence of Cancer Pain based on Pathophysiology in United Kingdom
    • 5.7.6. Incidence of Cancer Pain based on Temporal Variations in United Kingdom
    • 5.7.7. Incidence of Breakthrough Pain in United Kingdom
    • 5.7.8. Incidence of Cancer Pain based on duration in United Kingdom
  • 5.8. Japan
    • 5.8.1. Total Incident Cases of Advanced Stage Cancers in Japan
    • 5.8.2. Incidence of Cancer Pain based on Etiologies in Japan
    • 5.8.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan
    • 5.8.4. Severity Based Incidence of Cancer Pain on in Japan
    • 5.8.5. Total Incidence of Cancer Pain based on Pathophysiology in Japan
    • 5.8.6. Incidence of Cancer Pain based on Temporal Variations in Japan
    • 5.8.7. Incidence of Breakthrough Pain in Japan
    • 5.8.8. Incidence of Cancer Pain based on duration in Japan

6. Treatment and Management

  • 6.1. NCCN Guidelines
  • 6.2. ESMO Clinical Practice Guidelines
  • 6.3. Spanish Guidelines
  • 6.4. Multimodal Personalized Management of Cancer Pain
  • 6.5. Patient Journey
  • 6.6. The Role of Cannabinoids In Cancer Pain Management

7. Unmet Needs

8. Case Studies

  • 8.1. Case Studies in Pain Management: Cancer Pain
  • 8.2. Cancer-related visceral pain
  • 8.3. Complex Pain Management: Case study

9. Emerging drugs

  • 9.1. PPP011: Tetra Bio-Pharma Inc.
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical development
      • 9.1.3.1. Clinical Trials Information
    • 9.1.4. Product Profile
  • 9.2. Halneuron: Wex Pharma
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
      • 9.2.3.1. Clinical Trials Information
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. Tanezumab: Pfizer
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
      • 9.3.3.1. Clinical Trials Information
    • 9.3.4. Product Profile

10. Other Product of interest

  • 10.1. Tetrodotoxin: Wex Pharma
    • 10.1.1. Product Description
    • 10.1.2. Clinical development
      • 10.1.2.1. Clinical Trials Information
    • 10.1.3. Safety and Efficacy
    • 10.1.4. Product Profile
  • 10.2. Sativex: GW Pharmaceuticals
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical development
      • 10.2.3.1. Clinical Trials Information
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. NPC-06: Nobelpharma
    • 10.3.1. Product Description
    • 10.3.2. Product Development Activities
    • 10.3.3. Clinical development
      • 10.3.3.1. Clinical Trials Information
    • 10.3.4. Product Profile

11. Advanced Cancer Pain Management: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Advanced Cancer Pain Management in 7MM
  • 11.3. Market Outlook: 7MM
  • 11.4. Forecast Parameters
  • 11.5. United States Market Size
    • 11.5.1. Total Market size of Advanced Cancer Pain Management
    • 11.5.2. Market Size by Therapies

12. EU-5 Countries: Market Size

  • 12.1. Germany
    • 12.1.1. Total Market size of Advanced Cancer Pain Management in Germany
    • 12.1.2. Market Size by Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Advanced Cancer Pain Management
    • 12.2.2. Market Size by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Advanced Cancer Pain Management
    • 12.3.2. Market Size by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Advanced Cancer Pain Management
    • 12.4.2. Market Size by Therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Advanced Cancer Pain Management
    • 12.5.2. Market Size by Therapies

13. Japan: Market Size

  • 13.1. Japan Market Size
    • 13.1.1. Total Market Size of Advanced Cancer Pain Management
    • 13.1.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Bibliography
  • 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: Acute pain syndromes associated with antineoplastic treatments
  • Table 2: Chronic pain syndromes associated with cancer treatment
  • Table 3: Incidence of Cancer Pain based on Etiologies in 7MMin 7MM (2017-2028)
  • Table 4: Total Incidence of Advanced Stage Cancer in the United States (2017-2028)
  • Table 5: Incidence of Cancer Pain based on Etiologies in the United States (2017-2028)
  • Table 6: Incidence of CIPN in the United States (2017-2028)
  • Table 7: Severity Based Incidence of Cancer Pain in the United States (2017-2028)
  • Table 8: Pathophysiology Bases Cancer Pain in the United States (2017-2028)
  • Table 9: Incidence of Cancer Pain based on Temporal Variations in the United States (2017-2028)
  • Table 10: Incidence Breakthrough Pain in the United States (2017-2028)
  • Table 11: Incidence of Cancer Pain based on duration in the United States (2017-2028)
  • Table 12: Total Incidence of Advanced Stage Cancer in Germany (2017-2028)
  • Table 13: Incidence of Cancer Pain based on Etiologies in Germany (2017-2028)
  • Table 14: Incidence of CIPN in Germany(2017-2028)
  • Table 15: Severity Based Incidence of Cancer Pain in Germany (2017-2028)
  • Table 16: Pathophysiology Bases Cancer Pain Germany (2017-2028)
  • Table 17: Incidence of Cancer Pain based on Temporal Variations in Germany (2017-2028)
  • Table 18: Incidence Breakthrough Pain in Germany (2017-2028)
  • Table 19: Incidence of Cancer Pain based on duration in Germany (2017-2028)
  • Table 20: Total Incidence of Advanced Stage Cancer in France (2017-2028)
  • Table 21: Incidence of Cancer Pain based on Etiologies in France (2017-2028)
  • Table 22: Incidence of CIPN in France (2017-2028)
  • Table 23: Severity Based Incidence of Cancer Pain in France (2017-2028)
  • Table 24: Pathophysiology Bases Cancer Pain France (2017-2028)
  • Table 25: Incidence of Cancer Pain based on Temporal Variations in France (2017-2028)
  • Table 26: Incidence Breakthrough Pain in France (2017-2028)
  • Table 27: Incidence of Cancer Pain based on duration in France (2017-2028)
  • Table 28: Total Incidence of Advanced Stage Cancer in Italy (2017-2028)
  • Table 29: Incidence of Cancer Pain based on Etiologies in Italy (2017-2028)
  • Table 30: Incidence of CIPN in Italy(2017-2028)
  • Table 31: Severity Based Incidence of Cancer Pain in Italy (2017-2028)
  • Table 32: Pathophysiology Bases Cancer Pain Italy (2017-2028)
  • Table 33: Incidence of Cancer Pain based on Temporal Variations in Italy (2017-2028)
  • Table 34: Incidence Breakthrough Pain in Italy (2017-2028)
  • Table 35: Incidence of Cancer Pain based on duration in Italy (2017-2028)
  • Table 36: Total Incidence of Advanced Stage Cancer in Spain (2017-2028)
  • Table 37: Incidence of Cancer Pain based on Etiologies in Spain (2017-2028)
  • Table 38: Incidence of CIPN in Spain(2017-2028)
  • Table 39: Severity Based Incidence of Cancer Pain in Spain (2017-2028)
  • Table 40: Pathophysiology Bases Cancer Pain Spain (2017-2028)
  • Table 41: Incidence of Cancer Pain based on Temporal Variations in Spain (2017-2028)
  • Table 42: Incidence Breakthrough Pain in Spain (2017-2028)
  • Table 43: Incidence of Cancer Pain based on duration in Spain (2017-2028)
  • Table 44: Total Incidence of Advanced Stage Cancer in United Kingdom (2017-2028)
  • Table 45: Incidence of Cancer Pain based on Etiologies in United Kingdom (2017-2028)
  • Table 46: Incidence of CIPN in United Kingdom(2017-2028)
  • Table 47: Severity Based Incidence of Cancer Pain in United Kingdom (2017-2028)
  • Table 48: Pathophysiology Bases Cancer Pain United Kingdom (2017-2028)
  • Table 49: Incidence of Cancer Pain based on Temporal Variations in United Kingdom (2017-2028)
  • Table 50: Incidence Breakthrough Pain in United Kingdom (2017-2028)
  • Table 51: Incidence of Cancer Pain based on duration in United Kingdom (2017-2028)
  • Table 52: Total Incidence of Advanced Stage Cancer in Japan (2017-2028)
  • Table 53: Incidence of Cancer Pain based on Etiologies in Japan (2017-2028)
  • Table 54: Incidence of CIPN in Japan(2017-2028)
  • Table 55: Severity Based Incidence of Cancer Pain in Japan (2017-2028)
  • Table 56: Pathophysiology Bases Cancer Pain Japan (2017-2028)
  • Table 57: Incidence of Cancer Pain based on Temporal Variations in Japan (2017-2028)
  • Table 58: Incidence Breakthrough Pain in Japan (2017-2028)
  • Table 59: Incidence of Cancer Pain based on duration in Japan (2017-2028)
  • Table 60: Levels of evidence and grades of recommendation
  • Table 61: PPP011, Clinical Trial Description, 2020
  • Table 62: Haleneuron, Clinical Trial Description, 2020
  • Table 63: Tanezumab, Clinical Trial Description, 2020
  • Table 64: Tetrodotoxin, Clinical Trial Description, 2020
  • Table 65: Sativex, Clinical Trial Description, 2020
  • Table 66: NPC-06, Clinical Trial Description, 2020
  • Table 67: 7 Major Market Size of Advanced Cancer Pain Management in USD Million (2017-2028)
  • Table 68: United States Market Size of Advanced Cancer Pain Management in the US, USD Million (2017-2028)
  • Table 69: Market Size of Advanced Cancer Pain Management by Therapies in the US, in USD Million (2017-2028)
  • Table 70: Market Size of Advanced Cancer Pain Management in Germany, in USD Million (2017-2028)
  • Table 71: Market Size of Advanced Cancer Pain Management by Therapies in Germany, in USD Million (2017-2028)
  • Table 72: Market Size of Advanced Cancer Pain Management in France, in USD Million (2017-2028)
  • Table 73: Market Size of Advanced Cancer Pain Management by Therapies in France, in USD Million (2017-2028)
  • Table 74: Market Size of Advanced Cancer Pain Management in Italy, in USD Million (2017-2028)
  • Table 75: Market Size of Advanced Cancer Pain Management by Therapies in Italy, in USD Million (2017-2028)
  • Table 76: Market Size of Advanced Cancer Pain Management in Spain, in USD Million (2017-2028)
  • Table 77: Market Size of Advanced Cancer Pain Management by Therapies in Spain, in USD Million (2017-2028)
  • Table 78: Market Size of Advanced Cancer Pain Management in the UK, in USD Million (2017-2028)
  • Table 79: Market Size of Advanced Cancer Pain Management by Therapies in the UK, in USD Million (2017-2028)
  • Table 80: Market Size of Advanced Cancer Pain Management in Japan, in USD, Million (2017-2028)
  • Table 81: Market Size of Advanced Cancer Pain Management by Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Cancer pain etiologies
  • Figure 2: Incidence of Cancer Pain based on Etiologies in 7MM (2017-2028)
  • Figure 3: Total Incidence of Advanced Stage Cancer in the United States (2017-2028)

Figure4: Incidence of Cancer Pain based on Etiologies in the United States (2017-2028)

  • Figure 5: Incidence of CIPN in the United States (2017-2028)
  • Figure 6: Severity Based Incidence of Cancer Pain in the United States (2017-2028)
  • Figure 7: Pathophysiology Bases Cancer Pain in the United States (2017-2028)

Figure8: Incidence of Cancer Pain based on Temporal Variations in the United States (2017-2028)

  • Figure 9: Incidence Breakthrough Pain in the United States (2017-2028)
  • Figure 10: Incidence of Cancer Pain based on duration in the United States (2017-2028)
  • Figure 11: Total Incidence of Advanced Stage Cancer in Germany (2017-2028)

Figure12: Incidence of Cancer Pain based on Etiologies in Germany (2017-2028)

  • Figure 13: Incidence of CIPN in Germany (2017-2028)
  • Figure 14: Severity Based Incidence of Cancer Pain in Germany (2017-2028)
  • Figure 15: Pathophysiology Bases Cancer Pain in Germany (2017-2028)

Figure16: Incidence of Cancer Pain based on Temporal Variations in Germany (2017-2028)

  • Figure 17: Incidence Breakthrough Pain in Germany (2017-2028)
  • Figure 18: Incidence of Cancer Pain based on duration in Germany (2017-2028)
  • Figure 19: Total Incidence of Advanced Stage Cancer in France (2017-2028)

Figure20: Incidence of Cancer Pain based on Etiologies in France (2017-2028)

  • Figure 21: Incidence of CIPN in France (2017-2028)
  • Figure 22: Severity Based Incidence of Cancer Pain in France (2017-2028)
  • Figure 23: Pathophysiology Bases Cancer Pain in France (2017-2028)

Figure24: Incidence of Cancer Pain based on Temporal Variations in France (2017-2028)

  • Figure 25: Incidence Breakthrough Pain in France (2017-2028)
  • Figure 26: Incidence of Cancer Pain based on duration in France (2017-2028)
  • Figure 27: Total Incidence of Advanced Stage Cancer in Italy (2017-2028)

Figure28: Incidence of Cancer Pain based on Etiologies in Italy (2017-2028)

  • Figure 29: Incidence of CIPN in Italy (2017-2028)
  • Figure 30: Severity Based Incidence of Cancer Pain in Italy (2017-2028)
  • Figure 31: Pathophysiology Bases Cancer Pain in Italy (2017-2028)

Figure32: Incidence of Cancer Pain based on Temporal Variations in Italy (2017-2028)

  • Figure 33: Incidence Breakthrough Pain in Italy (2017-2028)
  • Figure 34: Incidence of Cancer Pain based on duration in Italy (2017-2028)
  • Figure 35: Total Incidence of Advanced Stage Cancer in Spain (2017-2028)

Figure36: Incidence of Cancer Pain based on Etiologies in Spain (2017-2028)

  • Figure 37: Incidence of CIPN in Spain (2017-2028)
  • Figure 38: Severity Based Incidence of Cancer Pain in Spain (2017-2028)
  • Figure 39: Pathophysiology Bases Cancer Pain in Spain (2017-2028)

Figure40: Incidence of Cancer Pain based on Temporal Variations in Spain (2017-2028)

  • Figure 41: Incidence Breakthrough Pain in Spain (2017-2028)
  • Figure 42: Incidence of Cancer Pain based on duration in Spain (2017-2028)
  • Figure 43: Total Incidence of Advanced Stage Cancer in United Kingdom (2017-2028)

Figure44: Incidence of Cancer Pain based on Etiologies in United Kingdom (2017-2028)

  • Figure 45: Incidence of CIPN in United Kingdom (2017-2028)
  • Figure 46: Severity Based Incidence of Cancer Pain in United Kingdom (2017-2028)
  • Figure 47: Pathophysiology Bases Cancer Pain in United Kingdom (2017-2028)

Figure48: Incidence of Cancer Pain based on Temporal Variations in United Kingdom (2017-2028)

  • Figure 49: Incidence Breakthrough Pain in United Kingdom (2017-2028)
  • Figure 50: Incidence of Cancer Pain based on duration in United Kingdom (2017-2028)
  • Figure 51: Total Incidence of Advanced Stage Cancer in Japan (2017-2028)

Figure52: Incidence of Cancer Pain based on Etiologies in Japan (2017-2028)

  • Figure 53: Incidence of CIPN in Japan (2017-2028)
  • Figure 54: Severity Based Incidence of Cancer Pain in Japan (2017-2028)
  • Figure 55: Pathophysiology Bases Cancer Pain in Japan (2017-2028)

Figure56: Incidence of Cancer Pain based on Temporal Variations in Japan (2017-2028)

  • Figure 57: Incidence Breakthrough Pain in Japan (2017-2028)
  • Figure 58: Incidence of Cancer Pain based on duration in Japan (2017-2028)
  • Figure 59: Modified World Health Organization Analgesic Ladder
  • Figure 60: Screening and Assessment for patients with cancer pain
  • Figure 61: Level of pain intensity for cancer patients
  • Figure 62: Management of patients in opioid tolerant patients
  • Figure 63: The analgesic trolley model for pain management
  • Figure 64: The analgesic trolley model for pain management
  • Figure 65: Patient Journey for ACPM
  • Figure 66: Unmet needs for ACPM
  • Figure 67: 7 Major Market Size of Advanced Cancer Pain Management in USD Million (2017-2028)
  • Figure 68: Market Size of Advanced Cancer Pain Management in the United States, USD Millions (2017-2028)
  • Figure 69: Market Size of Advanced Cancer Pain Management by Therapies in the US, in USD Million (2017-2028)
  • Figure 70: Market Size of Advanced Cancer Pain Management in Germany, USD Million (2017-2028)
  • Figure 71: Market Size of Advanced Cancer Pain Management by Therapies, in Germany, in USD Million (2017-2028)
  • Figure 72: Market Size of Advanced Cancer Pain Management in France, USD Million (2017-2028)
  • Figure 73: Market Size of Advanced Cancer Pain Management by Therapies, in France, in USD Million (2017-2028)
  • Figure 74: Market Size of Advanced Cancer Pain Management in Italy, USD Million (2017-2028)
  • Figure 75: Market Size of Advanced Cancer Pain Management by Therapies in Italy, in USD Million (2017-2028)
  • Figure 76: Market Size of Advanced Cancer Pain Management in Spain, USD Million (2017-2028)
  • Figure 77: Market Size of Advanced Cancer Pain Management by Therapies in Spain, in USD Million (2017-2028)
  • Figure 78: Market Size of Advanced Cancer Pain Management in the UK, USD Million (2017-2028)
  • Figure 79: Market Size of Advanced Cancer Pain Management by Therapies in the UK, in USD Million (2017-2028)
  • Figure 80: Market Size of Advanced Cancer Pain Management in Japan, USD Million (2017-2028)
  • Figure 81: Market Size of Advanced Cancer Pain Management by Therapies in Japan, in USD Million (2017-2028)
  • Figure 82: Market drivers for Advanced Cancer Pain Management
  • Figure 83: Market Barriers for Advanced Cancer Pain Management